FDA.reportPublic FDA data

Impavido

RxCUI
1495065
RxNorm name
Impavido
Term type
BN
Status
Active
Updated
2026-10-06 01:49:43

RxNorm Status History#

Status
Active
Source
RXNORM
Current
YES
Release start
052014
Active start
052014
Multiple ingredient
NO
Branded
YES

Derived Ingredient Concepts#

Ingredient, RxCUI table
IngredientRxCUI
miltefosine1494066

Source Vocabulary Codes#

Code type, Values, Count table
Code typeValuesCountCategory
PRESCRIBABLEY1ATTRIBUTES
RXNAV_STRImpavido1NAMES
RxNorm NameImpavido1NAMES
TTYBN1ATTRIBUTES
RxCUI14950651CODES
MMSL_CODEBN2134001CODES

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 0 matching rows.

No records found.

Drug Classes#

Source, Class ID, Class table
SourceClass IDClassTypeRelationshipDrug concept
ATCP01CXOther agents against leishmaniasis and trypanosomiasisATC1-4miltefosine
FDASPLN0000190851AntileishmanialEPChas_epcmiltefosine
MEDRTD010767PhosphorylcholineCHEMhas_ingredientmiltefosine
MEDRTD004342Drug HypersensitivityDISEASEci_withmiltefosine
MEDRTD016773Leishmaniasis, CutaneousDISEASEmay_treatmiltefosine
MEDRTD007898Leishmaniasis, VisceralDISEASEmay_treatmiltefosine
MEDRTD011247PregnancyDISEASEci_withmiltefosine
MEDRTD016111Sjogren-Larsson SyndromeDISEASEci_withmiltefosine
MEDRTN0000181812Lysophospholipid Receptor InteractionsMOAhas_moamiltefosine

Properties#

Category, Property, Value table
CategoryPropertyValue
ATTRIBUTESBN_CARDINALITYsingle
ATTRIBUTESGENERAL_CARDINALITYSINGLE
ATTRIBUTESRXNAV_HUMAN_DRUGUS
SOURCESSourceMultum MediSource Lexicon